{"analyses":[{"ciLowerLimit":"-2.06","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.59","groupDescription":"Difference in Numbness severity at baseline and week 10.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.56","paramType":"Mean Difference (Final Values)","paramValue":"-0.73","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.36","value":"1.38"},{"groupId":"OG001","spread":"1.79","value":"0.65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Participants reported the severity of two cognitive symptoms numbness on a 0-10 scale, with 0 being 'not present' and 10 being 'as bad as you can imagine': Higher mean scores indicate more severe symptoms.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received one pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.","id":"OG000","title":"Placebo Group"},{"description":"Participants received minocycline 200 mg orally for 1 dose, then 100 mg orally every 12 hours for 10 weeks beginning at initiation of induction therapy for multiple myeloma","id":"OG001","title":"Minocycline Group"}],"paramType":"MEAN","populationDescription":"Participants with quantitative sensory testing (QST) done a week prior to the start of their minocycline treatment and with corresponding QST at week 10","reportingStatus":"POSTED","timeFrame":"baseline and week 10","title":"Change in the Mean Value of Patient-reported MD Anderson Symptom Inventory for Multiple Myeloma (MDASI-MM) Numbness Scores From Baseline to Week 10 Post Treatment.","type":"SECONDARY","unitOfMeasure":"score on a scale"}